Lin-Wang Dong, MD
Cardiovascular Disease · Greeley, CONPI 1114064490
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Chiesi USA, Inc. at 37.9% of the total. Reporting peaked in 2024 at $1,497 and has fallen 80.7% since, to $289 in 2025.
Across 61 payments — averaging $51.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$1K
- Actelion Pharmaceuticals US, Inc.$499
- Bayer$420
- Abbott$374
- Vifor Pharma, Inc.$200
- United Therapeutics Corporation$149
- plus $322 from 9 others
Across 105 payments — averaging $6063.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$362K
- Actelion Pharmaceuticals, Ltd$120K
- Abbott$116K
- Livanova USA, Inc.$21K
- Janssen Research & Development, LLC$17K
What the payments were for
- Speaking & faculty fees$1,40044%
- Food & beverage$1,76456%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 1 | $1,200 |
| Actelion Pharmaceuticals US, Inc. | 21 | $499 |
| Bayer | 7 | $420 |
| Abbott | 12 | $374 |
| Vifor Pharma, Inc. | 1 | $200 |
| United Therapeutics Corporation | 3 | $149 |
| Merck | 2 | $101 |
| Philips North America LLC | 4 | $66 |
| Johnson & Johnson | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Gilead | 2 | $24 |
| Boston Scientific | 1 | $22 |
| Amgen | 1 | $18 |
| Novartis | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JUXTAPID$1,200
- Adempas$359
- Veltassa$200
- CARDIOMEMS$112
How this compares
$3,164 in reported general payments places this provider in the 60th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 224 | $2,821,736 |
| UptraviSelexipag | 96 | $2,341,839 |
| AdempasRiociguat | 136 | $1,928,478 |
| WinrevairSotatercept-Csrk | 19 | $359,823 |
| Ambrisentan | 137 | $336,300 |
| EliquisApixaban | 263 | $268,244 |
| XareltoRivaroxaban | 208 | $183,922 |
| Orenitram ErTreprostinil Diolamine | 28 | $156,904 |
| EntrestoSacubitril/Valsartan | 60 | $39,788 |
| Repatha SureclickEvolocumab | 35 | $27,522 |
| Bumetanide | 618 | $26,096 |
| Tadalafil | 34 | $22,633 |
| Sildenafil Citrate | 184 | $20,017 |
| OzempicSemaglutide | 17 | $14,818 |
| Potassium Chloride | 692 | $14,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $499 | $5,163,574320 claims |
| BayerAdempas | $420 | $1,928,478136 claims |
| MerckWinrevair | $101 | $359,82319 claims |
| Johnson & JohnsonXarelto | $42 | $183,922208 claims |
| NovartisEntresto | $12 | $39,78860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Greeley
- Paul HurstGreeley$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Deborah JalowiecColorado Springs$106K
- Edward GillAurora$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.